VX-973
/ Vertex
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
August 27, 2025
VX24-973-002: A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=30 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Completed
Trial completion • Pain
October 29, 2024
VX24-973-002: A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Recruiting
Enrollment open • Pain
September 26, 2024
A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated
New P1 trial • Pain
May 06, 2024
A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=30 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Active, not recruiting ➔ Completed | Trial completion date: Nov 2024 ➔ Apr 2024 | Trial primary completion date: Nov 2024 ➔ Apr 2024
Trial completion • Trial completion date • Trial primary completion date • Pain
April 05, 2024
A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=30 | Active, not recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Active, not recruiting | N=80 ➔ 30
Enrollment change • Enrollment closed • Pain
September 26, 2023
A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Trial completion date: Apr 2024 ➔ Nov 2024 | Trial primary completion date: Apr 2024 ➔ Nov 2024
Trial completion date • Trial primary completion date • Pain
May 19, 2023
A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated
New P1 trial • Pain
1 to 7
Of
7
Go to page
1